Literature DB >> 28455673

Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ.

Stephanie M Wong1, Tari King2, Jean-Francois Boileau1,3, William T Barry4, Mehra Golshan5.   

Abstract

PURPOSE: A diagnosis of lobular carcinoma in situ (LCIS) is associated with an increased risk of developing breast cancer, although little data exist on long-term patient outcomes, including those who develop subsequent breast malignancies.
METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify women with a histological diagnosis of LCIS between 1983 and 2014. The incidence and clinicopathologic features of subsequent malignancies were then examined, and the Kaplan-Meier method and multivariable Cox PH regression used to obtain breast cancer-specific survival (BCSS) estimates and associated hazard ratios.
RESULTS: Overall, 19,462 women swith a mean age at LCIS diagnosis of 53.7 years, and a 10- and 20-year cumulative incidence of subsequent breast malignancy of 11.3% [95% confidence interval (CI) 10.7-11.9%] and 19.8% (95% CI 18.8-20.9) met the eligibility criteria. At a median follow-up of 8.1 years (range 0-30.9) a total of 1837 primary breast cancers were diagnosed, of which 55.2% were diagnosed in the ipsilateral breast. Most breast cancers were of low/intermediate grade, hormone receptor-positive, and diagnosed in early stages. Of subsequent malignancies, invasive ductal carcinoma (IDC) distributed equally across both breasts, whereas invasive lobular carcinoma (ILC) was more likely to present in the ipsilateral breast (69.0% ILC vs. 49.2% IDC; p < 0.001). On multivariable analysis, type of surgical treatment for LCIS had no affect on long-term survival (p = 0.44). The 10- and 20-year BCSS for women with LCIS was 98.9 and 96.3%, respectively.
CONCLUSION: Women with LCIS who are diagnosed with a subsequent primary breast cancer are often diagnosed in early stages and have excellent BCSS.

Entities:  

Mesh:

Year:  2017        PMID: 28455673     DOI: 10.1245/s10434-017-5867-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  10 in total

1.  Surgical Management of Lobular Carcinoma In Situ: Analysis of the National Cancer Database.

Authors:  Lauren J Taylor; Jennifer Steiman; Jessica R Schumacher; Lee G Wilke; Caprice C Greenberg; Heather B Neuman
Journal:  Ann Surg Oncol       Date:  2018-05-31       Impact factor: 5.344

2.  Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ.

Authors:  Megan E Miller; Shirin Muhsen; Emily C Zabor; Jessica Flynn; Cristina Olcese; Dilip Giri; Kimberly J Van Zee; Melissa Pilewskie
Journal:  Ann Surg Oncol       Date:  2019-09-24       Impact factor: 5.344

Review 3.  Breast cancer screening for women at high risk: review of current guidelines from leading specialty societies.

Authors:  Natsuko Onishi; Masako Kataoka
Journal:  Breast Cancer       Date:  2020-09-21       Impact factor: 4.239

4.  Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ.

Authors:  Melissa Anne Mallory; Karissa Whiting; Anna Park; Mithat Gönen; Elizabeth Gilbert; Tari A King; Melissa L Pilewskie
Journal:  Breast Cancer Res Treat       Date:  2022-04-29       Impact factor: 4.872

Review 5.  The morphologic spectrum of lobular carcinoma in situ (LCIS) observations on clinical significance, management implications and diagnostic pitfalls of classic, florid and pleomorphic LCIS.

Authors:  Edi Brogi
Journal:  Virchows Arch       Date:  2022-05-14       Impact factor: 4.064

6.  Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS.

Authors:  Faina Nakhlis; Fisher D Katlin; Samantha C Grossmith; Ashley DiPasquale; Beth T Harrison; Stuart J Schnitt; Tari A King
Journal:  Ann Surg Oncol       Date:  2022-06-30       Impact factor: 4.339

Review 7.  Cancer Progress and Priorities: Breast Cancer.

Authors:  Serena C Houghton; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-05       Impact factor: 4.090

8.  Treatment and survival outcomes of lobular carcinoma in situ of the breast: a SEER population based study.

Authors:  Pu Cheng; Qi Huang; Jiafeng Shou; Guoming Hu; Mengjiao Han; Jian Huang
Journal:  Oncotarget       Date:  2017-10-03

9.  Prognostic Significance of Lobular Carcinoma In-Situ (LCIS) Diagnosed Alongside Invasive Breast Cancer.

Authors:  Maxwell C Braasch; Amanda L Amin; Christa R Balanoff; Jamie L Wagner; Kelsey E Larson
Journal:  Breast Cancer (Auckl)       Date:  2022-03-07

10.  The Selection of Treatment Modality for Breast Ductal Carcinoma In Situ: Experience From a Single Institution.

Authors:  Kai-Yun You; Zhuo-Fei Bi; Yu-Jia Ma; Yong-Lin Mao; Wei-Liang Zou; Yi-Min Liu; He-Rui Yao
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.